Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cellectis Inc.

< Previous 1 2 3 Next >
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS CLXT
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Announces Pricing of Follow-On Offering
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Announces Launch of Follow-On Offering
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS CLXT
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis to Report Third Quarter 2022 Financial Results
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022
From Cellectis Inc.
Via GlobeNewswire
Tickers CLLS
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.